Altered ratios of pro- and anti-angiogenic VEGF-A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma

Journal of Pathology

Volumn 239, Issue 2, 2016, Pages 139-151

  Ye, Xi ^a,b   Abou Rayyah, Yassir ^c   Bischoff, Joyce ^d   Ritchie, Alison ^b   Sebire, Neil J ^e   Watts, Patrick ^f   Churchill, Amanda J ^a,g   Bates, David O ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^g BRISTOL EYE HOSPITAL   (United Kingdom)

Author keywords

angiogenesis; endothelial cell; haemangioma; vascular endothelial growth factor

Indexed keywords

CD133 ANTIGEN; DELTA LIKE LIGAND 4; ISOPROTEIN; LIGAND; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; DLL4 PROTEIN, HUMAN; KDR PROTEIN, HUMAN; SIGNAL PEPTIDE; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CAPILLARY HEMANGIOMA; CELL DIFFERENTIATION; CELL DISRUPTION; CELL FUNCTION; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERICYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; ANIMAL; CANCER STEM CELL; CELL TRANSFORMATION; DISEASE MODEL; GENETICS; HEMANGIOMA; INFANT; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PRESCHOOL CHILD; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HEMANGIOMA; HUMANS; INFANT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84971619857     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4715     Document Type: Article

References (26)

1. Kilcline C, Frieden IJ,. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25: 168-173.
2. Drolet BA, Esterly NB, Frieden IJ,. Hemangiomas in children. N Engl J Med 1999; 341: 173-181.
3. Khan ZA, Boscolo E, Picard A, et al., Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008; 118: 2592-2599.
4. Boye E, Yu Y, Paranya G, et al., Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107: 745-752.
5. Greenberger S, Boscolo E, Adini I, et al., Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 2010; 362: 1005-1013.
6. Jinnin M, Medici D, Park L, et al., Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008; 14: 1236-1246.
7. Bates DO, Cui TG, Doughty JM, et al., VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62: 4123-4131.
8. Woolard J, Wang W, Bevan HS, et al., VEGF 165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64: 7822-7835.
9. Eswarappa SM, Potdar AA, Koch WJ, et al., Programmed translational readthrough generates anti-angiogenic VEGF-Ax. Cell 2014; 157: 1605-1618.
10. Hua J, Spee C, Kase S, et al., Recombinant human VEGF 165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2010; 51: 4282-4288.
11. Kawamura H, Li X, Harper SJ, et al., Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 2008; 68: 4683-4692.
12. Rennel E, Waine E, Guan H, et al., The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 2008; 98: 1250-1257.
13. Boscolo E, Mulliken JB, Bischoff J,. Pericytes from infantile hemangioma display pro-angiogenic properties and dysregulated Angiopoietin-1. Arter Thromb Vasc Biol 2013; 33: 501-509.
14. Boscolo E, Mulliken JB, Bischoff J,. VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma. Am J Pathol 2011; 179: 2266-2277.
15. Al Haj Zen A, Oikawa A, Bazan-Peregrino M, et al., Inhibition of Delta-like-4-mediated signaling impairs reparative angiogenesis after ischemia. Circ Res 2010; 107: 283-293.
16. Carter JG, Gammons MVR, Damodaran G, et al., The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy. Angiogenesis 2015; 18: 23-30.
17. Yu Y, Flint AF, Mulliken JB, et al., Endothelial progenitor cells in infantile hemangioma. Blood 2004; 103: 1373-1375.
18. Nowak DG, Woolard J, Amin EM, et al., Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 2008; 121: 3487-3495.
19. Merdzhanova G, Gout S, Keramidas M, et al., The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 2010; 29: 5392-5403.
20. Wood JM, Bold G, Buchdunger E, et al., PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
21. Detmar M, Yeo KT, Nagy JA, et al., Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995; 105: 44-50.
22. Khan ZA, Melero-Martin J, Wu X, et al., Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood 2006; 108: 915-921.
23. Ballmer-Hofer K, Andersson AE, Ratcliffe LE, et al., Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood 2011; 118: 816-826.
24. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, et al., Up-regulation of Delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005; 65: 8690-8697.
25. Camelo S, Raoul W, Lavalette S, et al., Delta-like 4 inhibits choroidal neovascularization despite opposing effects on vascular endothelium and macrophages. Angiogenesis 2012; 15: 609-622.
26. Hellström M, Phng LK, Hofmann JJ, et al., Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007; 445: 776-780.